Zolex Therapeutics is a recently established drug company focusing on the development of new classes of orally active, small-molecular-weight antibiotics that target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains. Zolex Therapeutics is located within the RadBioMed Accelerator at Ramat Hachayal, Tel Aviv, and is led by Dr. Lewis Neville and Dr. Ziv Lifshitz.